Julia Kuder

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca et al. · New England Journal of Medicine · 2018 · 6K citations · Full text

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease

Marc P. Bonaca, Patrice Nault, Robert P. Giugliano et al. · Circulation · 2017 · 731 citations · Full text

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

Marc S. Sabatine, Lawrence A. Leiter, Stephen D. Wiviott et al. · The Lancet Diabetes & Endocrinology · 2017 · 578 citations · Full text

Metabolic Syndrome, Hypertension, Diabetes Management +10

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

Eri Kato, Michael G. Silverman, Ofri Mosenzon et al. · Circulation · 2019 · 550 citations

Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death

Matthew A. Cavender, Philippe Gabríel Steg, Sidney C. Smith et al. · Circulation · 2015 · 491 citations · Full text